clairop

What to Take When Mesalamine Stops Working

When mesalamine stops working for ulcerative colitis, guidelines check inflammation, doses and infection first, then add rectal 5-ASA, steroids or advanced therapy.

Clairop Team29 min read

Photo: Marc Pell / Unsplash

The short answer

When mesalamine (5-ASA) stops controlling ulcerative colitis, guidelines first confirm that inflammation is active and rule out missed doses, infection and look-alike conditions. Next steps they list are optimizing the 5-ASA, often with a rectal form, a short steroid course as a bridge, then advanced therapy such as a biologic. Your gastroenterologist chooses; none of it is a do-it-yourself decision.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

When mesalamine (also called mesalamine or 5-ASA, an aminosalicylate anti-inflammatory used for ulcerative colitis) stops controlling your symptoms, guidelines do not jump straight to a new drug. They first confirm that inflammation is really active and rule out missed doses, infection and look-alike conditions. Then they list optimizing the 5-ASA, usually by adding a rectal form, a short steroid course as a bridge, and advanced therapy such as a biologic (Rubin 2025). Your gastroenterologist makes the choice.

This guide explains the logic of that ladder, what each rung is for, what the evidence says about it, and what to track so your appointment is productive. It is information, not advice about your treatment: we do not tell anyone to start, stop, switch or change any medicine, and nothing here ranks one drug above another for you. It is written from a US point of view first, with notes where the UK guidance differs. The American College of Gastroenterology (ACG) updated its ulcerative colitis guideline in 2025, the American Gastroenterological Association (AGA) publishes separate guidance for mild to moderate and for moderate to severe disease, and the British Society of Gastroenterology (BSG) has its own.

What does it mean when mesalamine stops working?

It means your symptoms or tests show ulcerative colitis is active despite an adequate dose of 5-ASA. Doctors separate two situations: 5-ASA that never gave a full remission, and 5-ASA that worked for years and then stopped. Both call for the same first move, which is to confirm that inflammation is really there. The opposite question, whether you can come off treatment altogether, is covered in can you live without medication with ulcerative colitis?.

Mesalamine is the standard first-line treatment for mild to moderate ulcerative colitis, and the guidelines are consistent about its role. In a 2026 comparison of the ECCO, AGA and ACG guidelines, 5-ASA remained a core option in mild to moderate UC and combined oral and rectal use was still supported in suitable patients (Shimomori 2026). It is also the drug people live on the longest, which is why a flare on it feels like a betrayal. A common theme in r/UlcerativeColitis is exactly that confusion: threads such as mesalamine not doing its job and mesalamine not really working are full of people asking whether "partly working" counts as working, and replies include people who say mesalamine alone never gave them full remission and people who say a change to the plan settled things.

The honest answer is that 5-ASA does not give everyone remission. The BSG summarizes the large dose-comparison trials: in ASCEND III, with 772 people with moderately active UC, remission at 6 weeks was 43% on the higher dose and 35% on the lower dose (Lamb 2019). Even in a trial setting with good adherence, a majority did not reach complete remission on the lower dose and a majority of the higher-dose arm did not either. That is not a failure of you. It is the expected ceiling of a modest-strength drug in moderate disease.

The ACG draws the practical conclusion in its key concepts: patients with mild to moderate UC who are not responsive to, or are intolerant of, 5-ASA should be treated as patients with moderate to severe disease (Guideline Central summary of the ACG 2025 guideline). That sentence is why the next sections matter: "mesalamine stopped working" is the doorway into the moderate to severe toolbox, but the guidelines want the door opened only after the checks below.

How do doctors check that mesalamine really has stopped working?

They confirm four things before changing treatment: that inflammation is objectively active, that the medicine is actually being taken as prescribed, that infection is excluded, and that the symptoms are not coming from something other than colitis. Each of these can mimic "mesalamine failure" and each has a different fix.

Is there inflammation? The ACG recommends using fecal calprotectin to assess response to therapy and to evaluate suspected relapse, and recommends treating to endoscopic improvement, defined as a Mayo endoscopic score of 0 or 1 (Rubin 2025). The AGA biomarker guideline suggests that in people whose symptoms are quiet, a calprotectin under 150 micrograms per gram, a normal lactoferrin or a normal CRP can be used to rule out active inflammation; in people with moderate to severe symptoms, a calprotectin over 150 can inform treatment decisions; and in people with mild symptoms, it suggests an endoscopic assessment (Singh 2023). Our guides to what calprotectin levels mean in ulcerative colitis and how long calprotectin results take cover the test itself.

Is the medicine actually reaching the bowel? Missed doses are the most common and most fixable cause. In a prospective study of 99 people with UC in remission on maintenance mesalamine, 12 had a relapse by 6 months and all 12 were nonadherent, defined as refilling less than 80% of their supply; over a year, nonadherent people had a more than fivefold higher risk of relapse (hazard ratio 5.5) (Kane 2003). A review of adherence in UC found it is poor outside clinical trials, and that patients name regimen complexity, number of tablets and dose frequency as the main barriers (Kane 2006). The ACG recommends that once-daily or more frequent oral dosing be chosen on patient preference, to optimize adherence, because efficacy and safety are no different (Rubin 2025). If you have been skipping doses, saying so is not confession; it is the most useful sentence in the appointment. The same goes for cost: if the price is why doses are slipping, read how to afford ulcerative colitis medication and tell your team before rationing anything.

Is it an infection? The ACG recommends stool testing to rule out Clostridioides difficile in people suspected of having UC and testing for it in acute severe disease. The BSG notes that C. difficile infection has been associated with worse outcomes in hospitalized IBD patients (Lamb 2019). A flare that follows a course of antibiotics, a stomach bug or travel needs that test before anyone decides a drug has failed.

Could it be the drug, or not colitis at all? The US label for one mesalamine tablet describes an acute intolerance syndrome in which symptoms may be difficult to distinguish from a UC exacerbation, and says to discontinue treatment if it is suspected; that decision belongs to the prescriber (DailyMed Lialda label). And a meta-analysis of 27 studies found that 32.5% of people with IBD in remission still reported IBS-type symptoms, falling to 23.5% when remission was confirmed by endoscopy, and a lower share in UC (28.7%) than in Crohn's (Fairbrass 2020). Gut symptoms without inflammation will not respond to a stronger anti-inflammatory, which is why the objective test comes first. Our article on ulcerative colitis symptoms while in remission goes into that group.

What it might beWhy it looks like failureHow it is usually checked
Active UC despite adequate 5-ASABlood, urgency, frequent stoolsCalprotectin, CRP, flexible sigmoidoscopy or colonoscopy
Missed or reduced dosesSymptoms return after a relapse-free spellCandid conversation, refill history, simpler regimen
Infection such as C. difficileSudden worsening, often after antibiotics or illnessStool test
Reaction to the medicineWorsening soon after a start or changeTiming review with prescriber or pharmacist
IBS-type symptomsBloating, urgency or loose stools with no inflammationNormal calprotectin or a scope showing healing

Can mesalamine be optimized before moving to something stronger?

Yes, and guidelines treat this as the first rung. For mild to moderate disease, they list confirming an adequate dose and adding a rectal 5-ASA, because oral and rectal 5-ASA together beat oral alone. They do not list swapping to another 5-ASA brand. Your doctor sets the dose, form and duration.

Here is what the guidelines actually say. The ACG calls a 5-ASA trial adequate at oral doses of at least 2 to 4.8 grams a day and/or at least 1 gram a day rectally, and, for people who fail to reach remission on that, suggests against changing to an alternative 5-ASA formulation and says other therapeutic classes should be considered (Guideline Central summary of the ACG 2025 guideline). Those are guideline reference points for what counts as a fair trial, not instructions for you to adjust anything. The BSG suggests that UC patients flaring on 5-ASA should receive dose escalation alongside 5-ASA enemas (Lamb 2019), and the AGA suggests high-dose mesalamine with rectal mesalamine in people with a suboptimal response to standard-dose oral therapy (Ko 2019).

Why does the rectal add-on help? The authors of one trial note that most clinical symptoms relate to disease activity in the distal part of the colon, which a rectal product reaches directly (Marteau 2005). A meta-analysis of 12 randomized trials found that combined oral and topical 5-ASA beat oral 5-ASA alone for inducing remission in active UC: in four trials, the relative risk of no remission was 0.65, and the number needed to treat was 5 (Ford 2012). A double-blind trial of 127 people with extensive mild to moderate UC, all on the same oral dose, found remission at week 8 in 64% of those who also used a mesalamine enema for the first four weeks versus 43% on a placebo enema (Marteau 2005). The BSG recommends adding enemas rather than oral treatment alone, even in extensive disease, and notes that the practical difficulty of administering and retaining enemas remains a major barrier (Lamb 2019).

That barrier is real, and it may be one reason a plan looks like it has failed: if a rectal product is prescribed and it is hard to use, it can quietly get skipped. In r/UlcerativeColitis, rectal products come up mostly as add-ons people are told they should have been offered, and one thread describes enemas that did not help either (thread). If a rectal product is the sticking point, raise that with your team rather than quietly dropping it. Different rectal forms exist, and the AGA mild to moderate guideline discusses how to choose between enemas, suppositories and foams according to where the disease is and what people tolerate (Ko 2019).

If your disease is limited to the rectum (proctitis), rectal therapy is the core treatment, not an add-on. A meta-analysis of 53 trials in ulcerative proctitis found topical 5-ASA beat placebo for induction (relative risk 2.72) and maintenance (2.09), topical steroids beat placebo for induction, and tacrolimus and etrasimod showed benefit in refractory cases (Aruljothy 2023). The ACG also notes that moderately to severely active isolated proctitis should be treated with therapies proven in more extensive UC of similar activity (Rubin 2025). See ulcerative proctitis versus ulcerative colitis for how the two are told apart.

Finally, there are things guidelines say are not established. The AGA makes no recommendation for probiotics or curcumin in mild to moderate UC and recommends fecal microbiota transplant only in clinical trials (Ko 2019), and the ACG finds insufficient evidence for probiotics, prebiotics or other alternative therapies as primary induction (Guideline Central summary of the ACG 2025 guideline). Lifestyle changes can matter for how you feel, but no guideline lists them as a substitute for the steps below.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

What do guidelines list after optimized 5-ASA fails?

For mild to moderate disease that stays active on optimized 5-ASA, guidelines list a short course of systemic steroids or oral budesonide MMX as the next step. For moderate to severe disease, or when 5-ASA fails, they list advanced therapies. The table summarizes the ladder and where each rung is meant to be used. For the benefits and risks laid side by side, see are biologics worth it for ulcerative colitis?.

StepWhat guidelines listIntended useLimits
1. Optimize 5-ASAAdequate oral dose, plus rectal 5-ASA; reassess in 8 weeksMild to moderate diseaseRectal products depend on tolerability
2. Add budesonide MMX or oral steroidsACG: budesonide MMX added in mild to moderate UC not responding to oral 5-ASA; oral systemic steroids for UC of any extent failing 5-ASAInduce remissionNot for maintenance; ACG recommends against
3. ImmunomodulatorThiopurine to keep steroid-induced remission; combined with infliximabSteroid-free maintenanceACG and AGA recommend against thiopurine or methotrexate alone to induce remission
4. Advanced therapyAnti-TNF, vedolizumab, ustekinumab, IL-23 inhibitors, JAK inhibitors, S1P modulatorsModerate to severe UC, steroid-dependent or refractory diseaseLabeled risks; first-line use gives higher response than after other failures

Not every guideline orders these identically. The AGA mild to moderate guideline suggests that in people refractory to optimized oral and rectal 5-ASA, oral prednisone or budesonide MMX be added (Ko 2019). The BSG recommends oral prednisolone for mild to moderate UC where 5-ASA induction fails or is not tolerated, and states that people on high-dose mesalamine who needed two or more steroid courses in the past year, or who become steroid-dependent or refractory, require escalation with a thiopurine, anti-TNF, vedolizumab or tofacitinib (Lamb 2019). The BSG also published an updated IBD guideline in 2025, which supersedes the 2019 document; we could read its abstract but not every statement, so the BSG statements quoted in this article come from the 2019 version and may have been refined since (Moran 2025). The ECCO also publishes its own treatment guideline, and the 2026 cross-guideline review found general agreement in direction among ECCO, AGA and ACG on 5-ASA in UC and the expanding role of advanced therapies (Shimomori 2026).

Are steroids the next step after mesalamine, and why are they only a bridge?

Often yes, for a short course. The ACG recommends oral systemic corticosteroids to induce remission in UC of any extent that fails 5-ASA, and recommends against systemic corticosteroids, budesonide MMX or topical corticosteroids for maintenance. Steroids calm a flare quickly, but they do not keep it calm, and a longer-term medicine is usually started alongside.

Budesonide MMX is a locally acting steroid with less absorption into the bloodstream. The ACG recommends it for induction in moderately active UC and, in mild to moderate UC not responding to oral 5-ASA, as an add-on, and the BSG says trials show it can induce remission in mild to moderate UC (Guideline Central summary of the ACG 2025 guideline; Lamb 2019). The ACG also notes that corticosteroids may be avoided entirely when other effective induction strategies are planned.

Why "bridge"? A population study from Olmsted County, Minnesota followed 63 people with UC who received a first course of systemic steroids between 1970 and 1993. At 30 days, 54% had a complete remission, 30% a partial one and 16% no response. A year later, 49% had a prolonged response, 22% were steroid-dependent and 29% had had an operation (Faubion 2001). Treatment has changed a great deal since then, so those numbers are a historical illustration, not a prediction, but they show why guidelines do not use steroids to hold remission. The BSG goes further, reserving oral prednisolone for people in whom 5-ASA has failed because of "significant side effects" (Lamb 2019).

Two r/UlcerativeColitis threads describe the same pattern in plain language: steroids brought calprotectin down or symptoms away, but things were not fully settled or came back as the dose fell, which led to a conversation about a longer-term drug (see this thread on mesalamine and a first round of steroids, and this one on the milder options). Anecdotes are not evidence, but they match the study. Whether a steroid course is right for you, and how it is tapered, is entirely your prescriber's decision. Never stop or reduce a steroid on your own, because stopping suddenly can itself cause problems.

Do you have to try every step before a biologic?

No. For moderate to severe disease, the AGA living guideline suggests early use of advanced therapies or immunomodulators rather than a gradual step-up after 5-ASA fails (Singh 2024). The ACG adds that patients with mild to moderate disease and several prognostic factors for hospitalization or surgery should be treated with therapies for moderate to severe disease (Rubin 2025).

This is the point where the Reddit consensus and the guidelines line up, and where the nuance matters. Many people in r/UlcerativeColitis say they wish they had moved to a biologic sooner (for example), and some say their doctor told them biologics are no longer a last resort for moderate to severe disease. That matches the AGA and ACG. But it applies to moderate to severe disease and to mild to moderate disease with poor prognostic markers, not to everyone with a bad month on mesalamine. The ACG is explicit that severity should be defined using symptoms, the burden of inflammation, the disease course (hospitalizations, steroid need, failure of medicines) and the impact on life, not symptoms alone (Guideline Central summary of the ACG 2025 guideline).

There is one more reason guidelines favor not waiting too long, which the ACG states in its key concepts: patients with moderately to severely active UC have higher rates of response and remission with their first advanced therapies than after failure of one or more others. The ACG also says that control of mucosal inflammation may reduce dysplasia risk (Rubin 2025). That is an argument for treating active inflammation, not an instruction about any particular person. Symptoms can also understate inflammation, which is why the STRIDE-II consensus lists endoscopic healing as a long-term target alongside clinical remission, with symptom relief and normalized calprotectin and CRP as shorter-term markers (Turner 2021). Our article on high calprotectin without symptoms explains why feeling fine and having quiet bowel are different things.

The flip side deserves equal weight. A forum thread is not a risk assessment. Several replies in those threads say they were frightened of stronger drugs, that a good conversation with a trusted doctor about quality of life and the risk of worsening disease helped, and a few describe side effects or a drug that stopped working. Both are true and both belong in the discussion with your doctor.

Where do azathioprine and mercaptopurine fit now?

Thiopurines still have a place, but a narrower one than they used to. The ACG recommends against thiopurine or methotrexate alone to induce remission in moderate to severe UC, suggests thiopurines to maintain a steroid-induced remission, and recommends combining infliximab with a thiopurine. They are not a replacement for stronger induction.

One popular Reddit claim is that these older drugs are "considered pretty old school" and that mesalamine leads "straight to biologics". The guidelines do not quite say that. The BSG reports that meta-analyzes consistently show a benefit of thiopurines over placebo for maintaining steroid-induced remission in UC, but not for inducing remission, and that a Cochrane review of four trials with 232 patients found failure in 44% on azathioprine versus 65% on placebo (Lamb 2019). The AGA suggests against thiopurine monotherapy for induction, but suggests it over no treatment for maintenance of typically steroid-induced remission, and suggests against methotrexate alone (Singh 2024). The ACG's maintenance statements say the same (Guideline Central summary of the ACG 2025 guideline).

Combination therapy is where thiopurines have the strongest evidence. In the UC SUCCESS trial of 239 anti-TNF-naive adults with moderate to severe UC, steroid-free remission at 16 weeks was 39.7% on infliximab plus azathioprine, 22.1% on infliximab alone and 23.7% on azathioprine alone (Panaccione 2014). Mucosal healing was 62.8%, 54.6% and 36.8%. The trial was stopped before its enrollment target, and combination therapy has its own risks, so the balance is for you and your prescriber. Some people in the threads say a daily thiopurine tablet works well for them alongside a biologic, and that is consistent with how combination therapy is used.

What classes of advanced therapy exist, and what do the labels warn about?

Advanced therapy means medicines that act on specific immune pathways: anti-TNF drugs, an integrin blocker, interleukin blockers, JAK inhibitors and S1P receptor modulators. The ACG recommends each class for inducing remission in moderate to severe UC. Each carries labeled risks and monitoring, which is why the choice is individual.

The ACG's list of recommended induction therapies for moderately to severely active UC includes the S1P receptor modulators ozanimod and etrasimod, the IL-12/23 antibody ustekinumab, the IL-23 inhibitors guselkumab, mirikizumab and risankizumab, vedolizumab, the anti-TNF drugs infliximab, adalimumab and golimumab, and the JAK inhibitors tofacitinib and upadacitinib (Guideline Central summary of the ACG 2025 guideline). The AGA living guideline uses similar groupings and sorts them into higher, intermediate and lower-efficacy tiers for people new to advanced therapy, and differently for people who have already been exposed to one (Singh 2024). But the ACG cautions that post hoc analyzes and network meta-analyzes are hypothesis-generating and not sufficient to stratify therapies for individual patients, and that there are no validated tests to predict who will respond to which drug. That is why this article does not rank them.

ClassExamples in the guidelinesWhat the labels and guidelines flag
Anti-TNFInfliximab, adalimumab, golimumabBoxed warning for serious infections and malignancy; TB testing before and monitoring during treatment (Remicade label)
Integrin blockerVedolizumabACG notes people at higher infection risk may benefit from vedolizumab or an anti-IL-23 strategy over more systemic options
IL-12/23 and IL-23 blockersUstekinumab, guselkumab, mirikizumab, risankizumabSame ACG note on infection risk; drug-specific labels differ
JAK inhibitorsTofacitinib, upadacitinibBoxed warnings for serious infections, mortality, malignancy, major cardiovascular events and thrombosis; TB testing (Rinvoq label, Xeljanz label)
S1P receptor modulatorsOzanimod, etrasimodDrug-specific labels; ask your prescriber about screening and monitoring

Several practical points follow from the guidelines. The ACG says initial and later therapy may be chosen on the basis of extraintestinal manifestations, such as joint or skin disease, where a drug has proven efficacy in both. It suggests against continuing 5-ASA purely for added efficacy once an advanced therapy has been started in people who failed 5-ASA, and the AGA suggests stopping it in that situation (Singh 2024). That is a decision for your prescriber, and never something to do on your own. The BSG states that the choice should reflect clinical factors, patient choice, cost, likely adherence and local infusion capacity (Lamb 2019). And the ACG says that third-party payers and step-therapy requirements should not come between a patient and their healthcare team in making treatment decisions. If your insurer insists on a different order, how to afford ulcerative colitis medication explains appeals and exceptions.

A frequent Reddit claim is that one particular drug is the "gentlest". There is partial support in the idea that gut-selective drugs may have different safety profiles, and the BSG says gut-selective therapy may be considered safer because of concerns about malignancy and infection, though there is little long-term data (Lamb 2019). But "gentlest" is not a verdict you can take from a forum, because the right drug depends on your disease, history and other conditions. We deliberately do not tell you which to choose. If a first advanced therapy does not work or stops working, what it means when a biologic stops working explains how doctors sort out the reasons, and the ACG's statement that primary and secondary non-response should be distinguished applies to every class.

If you are about to start one, our articles on what to expect at your first biologic infusion and why you need blood tests on a biologic cover the practicalities.

What if the fear of stronger drugs is the real sticking point?

Fear of stronger drugs is common and reasonable, and it is a conversation to have, not a reason to stay silent. In r/UlcerativeColitis threads such as from mesalamine to biologics, people ask whether moving on is a mistake. Replies mostly argue that uncontrolled inflammation carries risks of its own, and a minority describe side effects.

A few things help turn that fear into questions. Ask your gastroenterologist which risk numbers apply to your drug, your age and your other conditions, rather than reading them off a boxed warning written for every patient. Ask what monitoring would involve and how often. Ask what happens if the drug does not work, and what the next option would be. Ask whether a second opinion at an IBD center is reasonable, which it always is. Our questions to ask a gastroenterologist about colitis has a longer list. One thing the ACG makes clear is that patients should have all medical options available as recommended by their doctor, and that screening for anxiety and depression is part of UC care, so if the anxiety around treatment is heavy, say so.

How long should you wait before deciding mesalamine has failed?

Guidelines do not ask you to wait indefinitely. The ACG says people with mild to moderate UC should be reassessed to determine response to induction therapy within 8 weeks. If symptoms or calprotectin have not improved by then, the plan is usually revisited. Severe symptoms should never wait 8 weeks.

The BSG's induction trials use 6-week and 8-week endpoints (Lamb 2019), and the Pentasa trial assessed remission at 4 and 8 weeks (Marteau 2005). In practice, your doctor may want to see you sooner if symptoms are worse. A change in dose or form is also not an instant fix: remission in the trials above took weeks, not days. If you are anywhere inside that window, a progress check in clinic or through your portal is the right move, not a unilateral change.

What does not belong in the window is anything severe. The ACG's description of acute severe UC, and the BSG's before it, centers on frequent bloody stools with systemic signs. The BSG uses the modified Truelove and Witts criteria: more than six bloody stools a day plus systemic toxicity, meaning at least one of a temperature above 37.8 C, a pulse above 90 beats a minute, low hemoglobin or a raised CRP (Lamb 2019). That needs same-day care, not an outpatient conversation. See when to go to the hospital for a UC flare for the details.

What should you track and bring to the appointment?

Bring a timeline rather than a conclusion: stool count per day, blood on or in the stool, urgency, night-time bowel movements, missed or late doses, anything that changed around the time symptoms returned, and any test results with dates. Doctors use exactly these to confirm activity and decide the next step.

The reason it matters is that guideline definitions of severity rely on patient-reported outcomes such as bleeding, normalizing bowel habits and urgency, alongside objective markers and the disease course (Guideline Central summary of the ACG 2025 guideline). A clean record of those turns "it is not working" into something the team can act on. A few specifics help:

  • Doses, not just symptoms. Write down every missed or late dose, including rectal products. The adherence studies above show this is the single most informative detail.
  • Blood and nights. Days with blood and any bowel movements that wake you are among the signs that separate colitis from IBS-type symptoms, and they feed the PRO-2 score. Our guide to the PRO-2 score in ulcerative colitis explains it.
  • What else changed. Antibiotics, anti-inflammatory painkillers, an illness, travel, a new supplement or a changed product or brand.
  • Your test dates and results, so calprotectin, CRP and scope findings can be compared like with like. Our guide to how to track symptoms during a flare covers a simple routine.

If you use Clairop, its one-page report puts your bowel pattern, days with blood, overnight episodes, medication adherence and lab results in one view, which is the shape of information this conversation needs; you can see how it works on the how it works page. A paper log does the same job. It is patient-entered, it does not interpret anything and it cannot tell you what to take. If you want an app comparison, see apps for ulcerative colitis.

What do the myths get wrong?

Most myths about this situation reduce a guideline ladder to a single rule, such as "go up a dose" or "go straight to a biologic". The guidelines are more conditional than that: each step depends on severity, extent, prognosis and what has been tried. These are the ones that come up most often.

"If mesalamine is not working, I just need a higher dose." Sometimes dose and a rectal add-on are part of the plan, which is why guidelines list optimizing first. But the ACG suggests against switching 5-ASA brands once an adequate dose has failed and says other classes should be considered. The dose is not yours to change.

"Biologics are a last resort." The AGA and ACG list advanced therapies among standard recommended options for moderate to severe UC, and the AGA suggests early use rather than gradual step-up. That does not make them right for everyone, and it does not remove their labeled risks.

"Old drugs like azathioprine are obsolete." The ACG, AGA and BSG still list thiopurines for maintaining steroid-induced remission, and the ACG recommends combining infliximab with a thiopurine. They are not recommended alone for induction in moderate to severe UC.

"Steroids fixed it, so I am better." Steroids can induce remission quickly, but the ACG recommends against them for maintenance, and in the Minnesota study 22% of treated people were steroid-dependent a year later.

"If my symptoms are mild, my colon is fine." Not necessarily. Symptoms and inflammation do not always match, which is why STRIDE-II and the ACG both use objective markers and endoscopic healing as targets.

"I should stay on mesalamine because it is safe." Staying on an ineffective drug has its own risks if inflammation continues. The ACG notes that control of mucosal inflammation may reduce dysplasia risk. Whether to continue 5-ASA alongside anything else is the prescriber's decision.

"A forum told me which drug is best." The ACG says network meta-analyzes and subgroup analyzes are not sufficient to stratify therapies for an individual, and that no validated biomarker predicts response. The honest answer is "it depends on you".

What is the short version?

If mesalamine seems to have stopped working, do not change anything yourself, and do not wait out severe symptoms. Get objective confirmation of inflammation, be candid about doses and rectal products, ask about infection testing, and ask which rung of the ladder your team thinks you are on and why. For mild to moderate disease that is usually optimized 5-ASA with a rectal add-on, and a short steroid or budesonide MMX bridge if needed. For moderate to severe disease, or disease with poor prognostic markers, it may mean advanced therapy sooner rather than later, with a monitoring plan and a risk conversation tailored to you.

Every guideline cited here says the same thing in different words: the decision is individual, shared and revisited. A better appointment, built from a clear timeline, tests and honest questions, is the single thing in this process that is fully in your hands. If cost is part of the problem, read how to afford ulcerative colitis medication. If a later advanced therapy fades, when a biologic stops working is the next chapter.

How we wrote this, and what we could not verify. The ACG 2025 statements quoted here were read in Guideline Central's summary of the guideline, the BSG statements come from the full 2019 text, the AGA statements from the 2019 full text and the 2024 and 2023 abstracts, and trial figures from published abstracts or as summarized by the BSG. We could read only the abstract of the 2025 BSG update and could not read the ECCO treatment guideline text, so we do not attribute specific ECCO recommendations. No clinician has reviewed this article. Reddit threads show what people ask and report, never what works.

This article is general information, not medical advice. It does not replace your gastroenterologist, and it cannot tell you whether to start, stop or change any medicine.

Frequently asked questions

What do doctors prescribe when mesalamine stops working?
It depends on how active and how extensive the colitis is. Guidelines list optimizing the 5-ASA first, often by adding a rectal form, then a short steroid course or budesonide MMX for mild to moderate disease, and advanced therapies such as biologics, JAK inhibitors or S1P modulators for moderate to severe disease. Your gastroenterologist chooses after confirming inflammation.
How do I know mesalamine has really stopped working?
Symptoms alone are not enough. Doctors usually confirm active inflammation with a fecal calprotectin, blood markers or a scope, and check that doses are being taken, infection is excluded and the problem is not IBS-type symptoms. The ACG guideline suggests reassessing response to induction therapy within 8 weeks in mild to moderate disease.
Do I have to try every step before a biologic?
Not necessarily. For moderate to severe ulcerative colitis, the AGA living guideline suggests early use of advanced therapies or an immunomodulator rather than a gradual step-up after 5-ASA fails, and the ACG says mild to moderate disease that does not respond to 5-ASA should be treated like moderate to severe disease. The decision is made with your doctor.
Are steroids the next step after mesalamine?
Often as a bridge, not a plan. The ACG recommends oral corticosteroids to induce remission in UC of any extent that fails 5-ASA, and recommends against steroids for maintenance. In a population study, 22% of people with colitis treated with steroids were steroid-dependent a year later, which is why a longer-term medicine is usually started.
Is azathioprine outdated for ulcerative colitis?
Not outdated, but narrower. The ACG recommends against thiopurine or methotrexate alone to induce remission in moderate to severe UC, while the AGA and BSG describe thiopurines as useful to maintain remission that steroids achieved, and the ACG recommends combining infliximab with a thiopurine. Whether it suits you is a prescriber decision.
Can I add enemas or suppositories to my mesalamine?
Guidelines do list this as a standard next step, and a meta-analysis of four trials found combined oral and rectal 5-ASA beat oral 5-ASA alone for inducing remission (relative risk of no remission 0.65). But rectal products are prescription decisions: your doctor chooses the form, strength and duration, so ask rather than adding one yourself.
Can mesalamine itself make colitis symptoms worse?
Rarely, yes. The US label for one mesalamine tablet warns of an acute intolerance syndrome whose symptoms may be difficult to distinguish from a colitis flare, and of hypersensitivity reactions. If symptoms worsen soon after starting or changing a product, tell your prescriber or pharmacist promptly rather than stopping the medicine on your own.
Is it safe to go on a biologic after mesalamine?
Biologics and other advanced therapies carry real risks, including serious infections, which is why labels require tuberculosis screening and monitoring. They are also standard treatment recommended by the ACG and AGA for moderate to severe UC. Your doctor weighs those risks against the harm of uncontrolled inflammation for you. Ask for the numbers that apply to your drug and history.
What is the best app for tracking ulcerative colitis when changing treatment?
Clairop is one option: it turns stool pattern, blood, overnight episodes, PRO-2 score, medication adherence and lab results into a one-page report for your appointment. It is iPhone only and patient-entered, so your doctor interprets it. A paper log of stools, blood, urgency and missed doses does the same job.
What are the warning signs that need urgent care instead of waiting?
Seek urgent care for frequent bloody stools (the UC acute severe criteria include more than six a day), fever, a fast heartbeat, severe abdominal pain or swelling, vomiting, dizziness or being unable to keep fluids down. Do not wait for a routine appointment or adjust medication yourself; call your IBD team or emergency services.

Sources

  1. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-224. doi:10.14309/ajg.0000000000003463
  2. Guideline Central, with the American College of Gastroenterology. Updated 2025 ACG guidelines for ulcerative colitis in adults: summary of recommendations and key concepts. https://www.guidelinecentral.com/guideline/13311/
  3. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
  4. Moran GW, Gordon M, Sinopolou V, Radford SJ, Darie AM, Vuyyuru SK, et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74(Suppl 2):s1-s101. doi:10.1136/gutjnl-2024-334395
  5. Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748-64. doi:10.1053/j.gastro.2018.12.009
  6. Singh S, Loftus EV Jr, Limketkai BN, Haydek JP, Agrawal M, Scott FI, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307-43. doi:10.1053/j.gastro.2024.10.001
  7. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
  8. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577-85. doi:10.1111/j.1365-2036.2006.02809.x
  9. US National Library of Medicine. DailyMed: LIALDA (mesalamine) delayed-release tablets prescribing information, set id 3098a080-be86-4265-9818-7fc4beab77b7. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7
  10. Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053-62. doi:10.1016/S2468-1253(20)30300-9
  11. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344-72. doi:10.1053/j.gastro.2022.12.007
  12. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  13. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167-76. doi:10.1038/ajg.2011.410
  14. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960-5. doi:10.1136/gut.2004.060103
  15. Aruljothy A, Singh S, Narula N, et al. Systematic review with meta-analysis: medical therapies for treatment of ulcerative proctitis. Aliment Pharmacol Ther. 2023;58(8):740-62. doi:10.1111/apt.17666
  16. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-60. doi:10.1053/gast.2001.26279
  17. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3. doi:10.1053/j.gastro.2013.10.052
  18. US National Library of Medicine. DailyMed: RINVOQ (upadacitinib) prescribing information, set id 2966aec7-2ef0-923c-d8ff-fe1a957bf095. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095
  19. US National Library of Medicine. DailyMed: XELJANZ (tofacitinib) prescribing information, set id 68e3d6b2-7838-4d2d-a417-09d919b43e13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13
  20. US National Library of Medicine. DailyMed: REMICADE (infliximab) prescribing information, set id a0a046c1-056d-45a9-bfd9-13b47c24f257. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
  21. Shimomori Y, Yokoyama Y, Akita K, et al. A comparative review of inflammatory bowel disease guidelines: JSGE, ECCO, AGA, and ACG. EXCLI J. 2026;25:1516-26. doi:10.17179/excli2026-9575

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools